Outcomes in Systemic Sclerosis–Related Lung Disease After Lung Transplantation

• DOI: 10.1097/tp.0b013e3182845f23
• Publication Date: 2013-05-23T19:42:48Z
• Authors: Peter D. Sottile; David Iturbe; Tamiko R. Katsumoto; M. Kari Connolly; Harold R. Collard; Lorriana A. Leard; Steven Hays; Jeffrey A. Golden; Charles Hoopes; Jasleen Kukreja; Jonathan P. Singer
• Keywords: Contraindication

Background Lung disease is the leading cause of death in systemic sclerosis (SSc). The diagnosis SSc-related lung (SSc-LD) often a contraindication to transplantation (LT) due concerns that extrapulmonary involvement will yield worse outcomes. We sought evaluate posttransplantation outcomes persons with SSc-LD esophageal compared nonconnective tissue disease–related interstitial (nCTD-ILD). Methods From 1998 2012, undergoing LT for were age and gender matched 2:1 fashion controls nCTD-ILD. Esophageal function was assessed by pH testing manometry. defined dysfunction as presence DeMeester score >14 or dysmotility more severe than “mild nonspecific disorder”. primary outcome survival. Secondary included freedom from bronchiolitis obliterans syndrome (fBOS) rates acute rejection. Survival fBOS estimated Kaplan–Meier methods. Acute rejection Student’s t test. Results similar 23 46 who underwent (P=0.47). For group, 1- 5-year survival 83% 76% 91% 64% nCTD-ILD respectively. There no differences (P=0.83). Rates less SSc-ILD (P=0.05). not associated (P>0.55). Conclusions Persons appear have transplanted risk after may be reduced SSc-LD. does impact